Study of CPI-444 as a Single Agent and in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma

Condition:   Multiple Myeloma Interventions:   Drug: CPI-444;   Drug: daratumumab Sponsor:   Corvus Pharmaceuticals, Inc. Recruiting

Source: ClinicalTrials.gov - February 21, 2020 Category: Research Source Type: clinical trials